1	Out-of-Pocket Spending Within 90 Days of Discharge from COVID-19 Hospitalization
2	
3 4	Kao-Ping Chua, MD, PhD ^{a,b} , Rena M. Conti, PhD ^c , Nora V. Becker, MD, PhD ^d
5	Affiliations:
6	^a Department of Pediatrics, Susan B. Meister Child Health Evaluation and Research Center,
7	University of Michigan Medical School, Ann Arbor
8	
9	^b Department of Health Management and Policy, University of Michigan School of Public Health,
10	Ann Arbor
11	
12	^c Department of Markets, Public Policy, And Law, Institute for Health System Innovation and
13	Policy, Questrom School of Business, Boston University, Boston
14	
15	^d Department of Internal Medicine, Division of General Medicine, University of Michigan
16	Medical School, Ann Arbor
17	
18	Address correspondence to: Kao-Ping Chua, MD, PhD, 300 North Ingalls St, SPC 5456, Room
19	6E18, Ann Arbor, Michigan 48109-5456. E-mail: chuak@med.umich.edu. Phone: 734-615-
20	8169
21	
22	Conflicts of interest: The authors have no conflicts of interest to disclose.
23	
24	Financial disclosures: none
25	
26	Word count: 1199
27	
28	Date: June 15, 2021
29	
-	

30 ABSTRACT 31 32 **INTRODUCTION:** Millions of U.S. patients have been hospitalized for COVID-19. After 33 discharge, these patients often have extensive health care needs, but out-of-pocket burden for this care is poorly described. We assessed out-of-pocket spending within 90 days of discharge from 34 35 COVID-19 hospitalization among privately insured and Medicare Advantage patients. 36 **METHODS:** In May 2021, we conducted a cross-sectional analysis of the IQVIA PharMetrics[®] 37 Plus for Academics Database, a national de-identified claims database. Among privately insured 38 39 and Medicare Advantage patients hospitalized for COVID-19 between March-June 2020, we calculated mean out-of-pocket spending for care within 90 days of discharge. For context, we 40 repeated analyses for patients hospitalized for pneumonia. 41 42 43 **RESULTS:** Among 1,465 COVID-19 patients included, 516 (35.2%) and 949 (64.8%) were 44 covered by private insurance and Medicare Advantage plans. Among these patients, mean (SD) post-discharge out-of-pocket spending was \$534 (1,045) and \$680 (1,360); spending exceeded 45 46 \$2,000 for 7.0% and 10.3%. Compared with pneumonia patients, mean post-discharge out-ofpocket spending among COVID-19 patients was higher among the privately insured (\$534 vs 47 \$445) and lower among Medicare Advantage patients (\$680 vs \$918). 48 49 **CONCLUSIONS:** For the privately insured, post-discharge out-of-pocket spending was higher 50 among patients hospitalized for COVID-19 than among patients hospitalized for pneumonia. The 51 opposite was true for Medicare Advantage patients, potentially because insurer cost-sharing 52 waivers for COVID-19 treatment covered the costs of some post-discharge care, such as 53 54 COVID-19 readmissions. Nonetheless, given the high volume of U.S. COVID-19 55 hospitalizations to date, our findings suggest a large number of Americans have experienced 56 substantial financial burden for post-discharge care. 57

59 **INTRODUCTION**

80

60	Millions of U.S. patients have been hospitalized for coronavirus disease 2019 (COVID-
61	19). ¹ After discharge, these patients often have extensive health care needs. ²⁻⁴ However, out-of-
62	pocket burden for this care has been poorly described. Addressing this gap in knowledge is
63	crucial, as substantial out-of-pocket burden for post-discharge care might exacerbate other
64	financial stresses experienced by patients hospitalized for COVID-19, such as loss of
65	employment. ⁴ Using national claims data from privately insured and Medicare Advantage
66	patients, we assessed out-of-pocket spending within 90 days of discharge from COVID-19
67	hospitalizations during March-June 2020.
68	
69	METHODS
70	Study sample. In May 2021, we conducted a cross-sectional analysis of the IQVIA
70 71	<i>Study sample.</i> In May 2021, we conducted a cross-sectional analysis of the IQVIA PharMetrics [®] Plus for Academics Database, which contains medical and pharmacy claims from
71	PharMetrics [®] Plus for Academics Database, which contains medical and pharmacy claims from
71 72	PharMetrics [®] Plus for Academics Database, which contains medical and pharmacy claims from de-identified patients in all U.S. states. Data included 7.7 million patients covered by fully-
71 72 73	PharMetrics [®] Plus for Academics Database, which contains medical and pharmacy claims from de-identified patients in all U.S. states. Data included 7.7 million patients covered by fully-insured private plans and 1.0 million patients covered by Medicare Advantage plans in 2020.
71 72 73 74	PharMetrics [®] Plus for Academics Database, which contains medical and pharmacy claims from de-identified patients in all U.S. states. Data included 7.7 million patients covered by fully-insured private plans and 1.0 million patients covered by Medicare Advantage plans in 2020. Claims through September 30, 2020 were available at the time of analysis. Because data were
71 72 73 74 75	PharMetrics [®] Plus for Academics Database, which contains medical and pharmacy claims from de-identified patients in all U.S. states. Data included 7.7 million patients covered by fully- insured private plans and 1.0 million patients covered by Medicare Advantage plans in 2020. Claims through September 30, 2020 were available at the time of analysis. Because data were de-identified, the Institutional Review Board of the University of Michigan Medical School
71 72 73 74 75 76	PharMetrics [®] Plus for Academics Database, which contains medical and pharmacy claims from de-identified patients in all U.S. states. Data included 7.7 million patients covered by fully- insured private plans and 1.0 million patients covered by Medicare Advantage plans in 2020. Claims through September 30, 2020 were available at the time of analysis. Because data were de-identified, the Institutional Review Board of the University of Michigan Medical School

81 during this period. We excluded patients without continuous medical and pharmacy coverage

3

ended between March 1-June 30, 2020. We limited analyses to each patient's first hospitalization

during the 90 days after discharge, patients whose plan was the secondary insurer, and patients
with missing out-of-pocket spending data on any claim during the 90 days after discharge.

84

85 *Measures.* We calculated mean out-of-pocket spending (sum of deductibles, co-86 insurance, and co-payments) across all claims during the 90 days after discharge. Additionally, 87 we calculated mean out-of-pocket spending for 14 service categories: additional hospitalizations, nursing facility admissions, outpatient (e.g., office visits), emergency department visits, 88 radiology, laboratory, diagnostic/therapeutic procedures (e.g., colonoscopy, surgery), 89 90 physical/occupational/speech/respiratory therapy, home health/hospice, transportation, clinicianadministered medications (e.g., infusions), durable medical equipment and supplies, pharmacy-91 dispensed prescriptions, and miscellaneous (Appendix). For context, we repeated analyses 92 among patients hospitalized for bacterial pneumonia. These patients met similar inclusion and 93 exclusion criterion and did not overlap with the main sample. 94 95 Statistical analyses. Within payer types, we compared post-discharge out-of-pocket 96 spending between COVID-19 and pneumonia patients using a one-part generalized linear model 97 with a log link and Poisson variance function, chosen based on the modified Park test.⁵ Models 98 99 adjusted for age group, sex, Census region of residence, and month of admission. Analyses used SAS 9.4, Stata 15.1 MP, and two-sided hypothesis tests with $\alpha = 0.05$. 100 101

102 **RESULTS**

Of 2,275 COVID-19 patients meeting inclusion criteria, 810 (35.8%) were excluded,
leaving 1,465 patients. Table 1 displays sample characteristics. Overall, 516 (35.2%) and 949
(64.8%) patients were covered by private insurance and Medicare Advantage plans.

106	Among privately insured patients, mean (SD) post-discharge out-of-pocket spending was
107	\$534 (1,045). For 36 (7.0%) and 15 (2.9%) patients, this spending exceeded \$2,000 and \$4,000.
108	Service categories accounting for the most out-of-pocket spending were pharmacy-dispensed
109	prescriptions (\$130; 24.4% of out-of-pocket spending) and hospitalizations (\$111; 20.8%).
110	Among Medicare Advantage patients, mean post-discharge out-of-pocket spending was \$680
111	(1,360). For 98 (10.3%) and 34 (3.6%) patients, this spending exceeded \$2,000 and \$4,000.
112	Service categories accounting for the most out-of-pocket spending were hospitalizations (\$183;
113	27.0%) and nursing facility admissions (\$126; 18.6%) (Table 2). Among privately insured and
114	Medicare Advantage patients, 43.5% and 40.3% of out-of-pocket spending for pharmacy-
115	dispensed prescriptions was for anticoagulants, diabetes drugs (e.g., insulin and sulfonylureas),
116	and bronchodilators. In both populations, these medication classes accounted for the 3 highest
117	shares of out-of-pocket spending for pharmacy-dispensed prescriptions.
118	
119	Table 1 displays characteristics of the 1,374 patients hospitalized for pneumonia included
120	in analyses. Among the 245 privately insured pneumonia patients, mean (SD) post-discharge out-
121	of-pocket spending was \$450 (924), compared with \$534 among COVID-19 patients (adjusted
122	difference: -\$131, 95% CI: -\$135, -\$128). Among the 1,129 Medicare Advantage patients, mean
123	(SD) post-discharge out-of-pocket spending was \$918 (1,263), compared with \$680 among
124	COVID-19 patients (adjusted difference: \$291, 95% CI: \$288, \$294). Among 370 Medicare
125	Advantage patients with additional hospitalizations after a pneumonia hospitalization, 306
126	(82.7%) had out-of-pocket spending for the additional hospitalizations. Among 206 Medicare
127	Advantage patients with additional hospitalizations after a COVID-19 hospitalization, 141

129 DISCUSSION

During the 90 days after COVID-19 hospitalization, privately insured and Medicare Advantage patients paid an average of \$534 and \$680 for health care; 7.0% and 10.3% of patients paid more than \$2,000. For privately insured patients, prescriptions and additional hospitalizations accounted for the highest shares of out-of-pocket spending. For Medicare Advantage patients, additional hospitalizations and nursing facility admissions accounted for the highest shares.

136

137 For the privately insured, post-discharge out-of-pocket spending was higher among patients hospitalized for COVID-19 than among patients hospitalized for pneumonia. Perhaps 138 surprisingly, the opposite was true for Medicare Advantage patients. A potential explanation is 139 140 that some post-discharge care for COVID-19 patients, including readmissions for COVID-19, were covered by insurer cost-sharing waivers for COVID-19 treatment.⁶ In support of this 141 142 possibility, Medicare Advantage patients who had additional hospitalizations after a COVID-19 143 hospitalization were less likely to have out-of-pocket spending for the additional hospitalizations 144 compared with pneumonia patients. As many insurers allowed their cost-sharing waivers to expire in early 2021⁷, post-discharge out-of-pocket spending among patients hospitalized for 145 146 COVID-19 could now be higher than among study patients.

147

Even if out-of-pocket spending after COVID-19 hospitalization is not greater than for other conditions, our findings suggest a large number of Americans have experienced substantial post-discharge out-of-pocket spending given the volume of COVID-19 hospitalizations to date. To illustrate this point, national data estimate that 2.25 million COVID-19 hospitalizations

occurred between August 1, 2020 and June 13, 2021.¹ If 1 in 14 hospitalizations resulted in post-152 discharge out-of-pocket spending exceeding \$2,000 – the rate for privately insured patients in 153 our study – this would translate to roughly 160,000 hospitalizations and more than \$320 million 154 155 billed to patients for post-discharge care. Importantly, the expiration of insurer cost-sharing waivers means that many patients will now be billed for the COVID-19 hospitalization itself, 156 adding further financial burden beyond that associated with post-discharge care. Consequently, 157 158 monitoring the financial health of patients hospitalized for COVID-19 is a key policy priority 159 going forward.

160

This study has limitations. First, analyses only captured the immediate period after 161 COVID-19 hospitalization. Second, the post-discharge period in this study occurred during the 162 163 early stages of the pandemic, when health care utilization decreased sharply owing partly to social distancing measures.⁸ Post-discharge utilization, and therefore out-of-pocket spending, 164 165 might be higher now that utilization is rebounding. Third, this study required hospital discharge 166 by June 30, 2020 because a 90-day post-discharge period was needed and claims were complete only through September 30, 2020 at the time of analysis. While necessary, this decision excluded 167 patients with prolonged hospitalizations who may require intensive post-discharge care. 168 Consequently, analyses likely underestimate out-of-pocket burden among all patients 169 170 hospitalized for COVID-19. Finally, patients may not be fully representative of the entire 171 privately insured and Medicare Advantage population. 172 173

174

175 CONCLUSIONS

- 176 In this national cohort of 1,465 patients hospitalized for COVID-19 during March-June
- 177 2020, out-of-pocket spending within 90 days of discharge exceeded \$2,000 for 1 in 14 privately
- 178 insured patients and 1 in 10 Medicare Advantage patients. Future studies should repeat analyses
- among patients more recently hospitalized for COVID-19 using longer follow-up periods.

180 ACKNOWLEDGEMENTS

Author Contributions: Dr. Chua had full access to all of the data in the study and takes
responsibility for the integrity of the data and the accuracy of the data analysis.
Kao-Ping Chua: Conceptualization, Methodology, Software, Formal analysis, Writing – original
draft, Data curation, Writing – review and editing, Visualization, Funding acquisition
Rena Conti: Conceptualization, Methodology, Formal analysis, Writing – review and editing

- 189 Nora Becker: Conceptualization, Methodology, Formal analysis, Writing review and editing,
 190 Supervision.
- 191
- **Funding source:** Funding for purchasing IQVIA data was partially provided by the Susan B.
- 193 Meister Child Health Evaluation and Research Center at the University of Michigan Medical
- 194 School. Dr. Chua's effort is supported by a career development award from the National Institute
- on Drug Abuse (grant number 1K08DA048110-01). The funders played no role in the design and
- 196 conduct of the study; collection, management, analysis, and interpretation of the data;
- 197 preparation, review, or approval of the manuscript; and decision to submit the manuscript for
- 198 publication
- 199
- 200 **Conflicts of interest:** The authors have no conflicts of interest to disclose.
- 201

202 **REFERENCES**

- Centers for Disease Control and Prevention. Covid Data Tracker. [Internet]. 2021;
 <u>https://covid.cdc.gov/covid-data-tracker/#new-hospital-admissions</u>. Accessed June 3, 205
- Lavery AM, Preston LE, Ko JY, et al. Characteristics of Hospitalized Covid-19 Patients
 Discharged and Experiencing Same-Hospital Readmission United States, March-August
 208 2020. MMWR Morb Mortal Wkly Rep. 2020;69(45):1695-1699.
- Weerahandi H, Hochman KA, Simon E, et al. Post-Discharge Health Status and
 Symptoms in Patients with Severe Covid-19. *J Gen Intern Med.* 2021;36(3):738-745.
- 4. Chopra V, Flanders SA, O'Malley M, Malani AN, Prescott HC. Sixty-Day Outcomes among Patients Hospitalized with Covid-19. *Ann Intern Med.* 2021;174(4):576-578.
- 5. Buntin MB, Zaslavsky AM. Too Much Ado About Two-Part Models and
 Transformation? Comparing Methods of Modeling Medicare Expenditures. *Journal of*
- 215 *Health Economics*, 2004:23:525-542.
- America's Health Insurance Plans. Health Insurance Providers Respond to Coronavirus (Covid-19). [Internet]. 2021; <u>https://www.ahip.org/health-insurance-providers-respond-</u>
 to-coronavirus-covid-19. Accessed May 25, 2021.
- Appleby J. Time to Say Goodbye to Some Insurers' Waivers for Covid Treatment Fees.
 [Internet]. 2021; <u>https://khn.org/news/article/time-to-say-goodbye-to-some-insurers-</u>
 waivers-for-covid-treatment-fees/. Accessed May 25, 2021.
- Cox C, Amin K, Kamal R. How Have Health Spending and Utilization Changed During the Coronavirus Pandemic? 2021; <u>https://www.healthsystemtracker.org/chart-</u>
- 224 <u>collection/how-have-healthcare-utilization-and-spending-changed-so-far-during-the-</u>
 225 <u>coronavirus-pandemic/#item-start</u>. Accessed June 9, 2021.
- 226

Table 1. Characteristics of patients hospitalized for COVID-19 and pneumonia between March-June 2020, IQVIA PharMetrics[®] Plus for Academics Database

	COVID-19 (n= 2	1,465) ^a	Pneumonia (n = 1,374) ^b			
	Private insurance	Medicare Advantage	Private insurance	Medicare Advantage		
Number of patients	516	949	245	1,129		
Age in years						
0-17	6 (1.2%)	0 (0.0%)	17 (6.9%)	0 (0.0%)		
18-34	33 (6.4%)	4 (0.4%)	25 (10.2%)	0 (0.0%)		
35-54	226 (43.8%)	44 (4.6%)	86 (35.1%)	67 (5.9%)		
55-64	202 (39.1%)	102 (10.7%)	99 (40.4%)	168 (14.9%)		
65-74	45 (8.7%)	319 (33.6%)	14 (5.7%)	379 (33.6%)		
75-85	3 (0.6%)	319 (33.6%)	4 (1.6%)	350 (31.0%)		
≥ 86	1 (0.2%)	161 (17.0%)	0 (0.0%)	165 (14.6%)		
Sex						
Male	322 (62.4%)	411 (43.3%)	121 (49.4%)	532 (47.1%)		
Female	194 (37.6%)	538 (56.7%)	124 (50.6%)	597 (52.9%)		
Region						
Northeast	150 (29.1%)	467 (49.2%)	25 (10.2%)	146 (12.9%)		
Midwest	122 (23.6%)	308 (32.5%)	56 (22.9%)	617 (54.7%)		
South	165 (32.0%)	110 (11.6%)	113 (46.1%)	275 (24.4%)		
West	76 (14.7%)	62 (6.5%)	51 (20.8%)	90 (8.0%)		
Admission month						
March	85 (48.1%)	143 (54.7%)	117 (24.1%)	447 (23.1%)		
April	248 (18.8%)	519 (20.7%)	59 (16.7%)	261 (21.8%)		
May	97 (16.7%)	196 (9.6%)	41 (11.4%)	246 (15.5%)		
June	86 (16.7%)	91 (9.6%)	28 (11.4%)	175 (15.5%)		
Mean length of stay (SD)	7.9 (8.2)	8.9 (7.9)	4.2 (4.2)	4.6 (3.4)		
Any intensive care unit utilization ^a	239 (46.3%)	339 (35.7%)	86 (35.1%)	437 (38.7%)		

^aAmong 2,275 patients with an initial hospitalization for COVID-19 between March 1-June 30, 2020, 747 were excluded because they lacked continuous enrollment during the 90 days after discharge, 54 because their insurance was not primary, and 8 because of missing data for out-of-pocket spending. We excluded 1 additional patient owing to the occurrence of a hospitalization that had not resulted in discharge by September 30, 2020 (raising the possibility that out-of-pocket spending for this hospitalization was not fully observed). In total, 810 patients were excluded, leaving 1,465 COVID-19 patients.

^bWe identified 1,810 patients who had a hospitalization with a primary diagnosis code for bacterial pneumonia (ICD-10-CM diagnosis code J13-J18) and no secondary diagnosis code for COVID-19 (U017) between March 1-June 30, 2020, and who were not in the sample of 1,465 COVID-19 patients. Of the 1,813 patients, 365 were excluded because they lacked continuous enrollment during the 90 days after discharge, 47 because their insurance was not primary, 22 because of missing data for out-of-pocket spending, and 2 because they had a hospitalization that had not resulted in discharge by September 30, 2020. In total, 436 patients were excluded, leaving 1,374 pneumonia patients.

^cDefined as having at least one claim during the hospitalization with a revenue code for intensive care unit (0200-0209) or coronary care unit (0210-0219).

Table 2. Out-of-pocket spending for health care in the 90 days after COVID-19 hospitalization, IQVIA PharMetrics[®] Plus for Academics Database

	Private insurance (n = 516)					Medicare Advantage (n = 949)				
Service category ^a	No. patients with ≥1 claim (% patients in sample)	Mean (SD) OOP spending per patient in sample	% of all OOP spending	No. patients with OOP spending (% patients in sample)	Mean (SD) OOP spending among patients with OOP spending	No. patients with ≥1 claim (% patients in sample)	Mean (SD) OOP spending per patient in sample	% of all OOP spending	No. patients with OOP spending (% patients in sample)	Mean (SD) OOP spending among patients with OOP spending
Hospitalization	56 (10.9%)	\$111 (638)	20.8%	35 (6.8%)	\$1634 (1896)	206 (21.7%)	\$183 (824)	27.0%	141 (14.9%)	\$1235 (1815)
Nursing facility	2 (0.4%)	\$0(12)	0.1%	1 (0.2%)	\$281 (NA)	221 (23.3%)	\$126 (698)	18.6%	128 (13.5%)	\$936 (1695)
Outpatient services	450 (87.2%)	\$44 (100)	8.2%	223 (43.2%)	\$101 (132)	797 (84.0%)	\$36 (57)	5.2%	497 (52.4%)	\$68 (6 <u>4)</u>
ED visits	56 (10.9%)	\$31 (190)	5.9%	25 (4.8%)	\$647 (597)	183 (19.3%)	\$13 (49)	1.9%	103 (10.9%)	\$121 (97)
Radiology tests	223 (43.2%)	\$65 (239)	12.2%	120 (23.3%)	\$280 (431)	404 (42.6%)	\$36 (166)	5.3%	241 (25.4%)	\$142 (30) ÷
Laboratory tests	320 (62.0%)	\$41 (207)	7.8%	139 (26.9%)	\$154 (377)	632 (66.6%)	\$7 (20)	1.0%	282 (29.7%)	\$23 (3) 2
Procedures	188 (36.4%)	\$58 (300)	10.9%	100 (19.4%)	\$301 (628)	485 (51.1%)	\$97 (430)	14.2%	271 (28.6%)	\$338 (7 5 \$) 🛱 🔀
PT, OT, ST, RT	37 (7.2%)	\$9 (75)	1.7%	16 (3.1%)	\$292 (323)	114 (12.0%)	\$9 (50)	1.3%	58 (6.1%)	\$141 (15) 🖉 💆
Home health and hospice	76 (14.7%)	\$6 (72)	1.1%	10 (1.9%)	\$290 (456)	192 (20.2%)	\$3 (14)	0.4%	66 (7.0%)	\$38 (4 J)
Transportation	11 (2.1%)	\$4 (65)	0.8%	4 (0.8%)	\$526 (595)	162 (17.1%)	\$33 (186)	4.8%	98 (10.3%)	\$319 (4%夏星 <mark>1</mark> 2
Administered medications ^b	98 (19.0%)	\$6 (62)	1.1%	38 (7.4%)	\$78 (216)	214 (22.6%)	\$26 (259)	3.8%	73 (7.7%)	\$332 (88 ⁹ 4) 5
DME and supplies	476 (92.2%)	\$12 (51)	2.3%	55 (10.7%)	\$114 (115)	906 (95.5%)	\$10 (61)	1.5%	179 (18.9%)	\$56 (13) 🛱 🎖
Pharmacy ^c	459 (89.0%)	\$130 (261)	24.4%	420 (81.4%)	\$160 (282)	837 (88.2%)	\$87 (212)	12.9%	649 (68.4%)	\$128 (24 7)§
Miscellaneous	179 (34.7%)	\$15 (131)	2.8%	31 (6.0%)	\$253 (480)	381 (40.1%)	\$14 (118)	2.1%	66 (7.0%)	\$207 (40 <mark>4</mark>) 2 \overline{s}
Any service category	510 (98.8%)	\$534 (1045)	100.0%	453 (87.8%)	\$608 (1095)	939 (98.9%)	\$680 (1360)	100.0%	868 (91.5%)	\$743 (1405) §

OOP – out-of-pocket; ED – emergency department; PT – physical therapy; OT – occupational therapy; ST – speech therapy; RT – respiratory therapy; DME – durable medical equipment; NA: not-applicable

^aThese service categories were based on the Agency for Healthcare Research and Quality Clinical Classification Software algorithm for procedures, v2020-1 (available at https://www.hcup-us.ahrq.gov/toolssoftware/ccs_svcsproc/ccssvcproc.jsp). See Appendix for details.

^bAdministered medications refer to medications administered by clinciains, such as injections and infusions at visits

^cIncludes prescriptions dispensed at pharmacies